Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice
Mar Cuadrado‐Tejedor, Carolina García, Juan A. Sánchez‐Arias, et al.
Neuropsychopharmacology (2016) Vol. 42, Iss. 2, pp. 524-539
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

A histone acetylome-wide association study of Alzheimer’s disease identifies disease-associated H3K27ac differences in the entorhinal cortex
Sarah J. Marzi, Szi Kay Leung, Teodora Ribarska, et al.
Nature Neuroscience (2018) Vol. 21, Iss. 11, pp. 1618-1627
Closed Access | Times Cited: 180
Polypharmacology: The science of multi-targeting molecules
Abbas Kabir, Aaron Muth
Pharmacological Research (2022) Vol. 176, pp. 106055-106055
Closed Access | Times Cited: 101
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
Shuangshuang Yang, Rui Zhang, Gang Wang, et al.
Translational Neurodegeneration (2017) Vol. 6, Iss. 1
Open Access | Times Cited: 133
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu, Yichao Wan, Yuliang Xiao, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8977-9002
Closed Access | Times Cited: 130
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 127
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease
Yinuo Wu, Zhe Li, Yi‐You Huang, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 13, pp. 5467-5483
Closed Access | Times Cited: 108
GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia
Mengyi Xu, Albert H.C. Wong
Acta Pharmacologica Sinica (2018) Vol. 39, Iss. 5, pp. 733-753
Open Access | Times Cited: 106
Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors
Wesam S. Ahmed, Anupriya M. Geethakumari, Kabir H. Biswas
Biomedicine & Pharmacotherapy (2020) Vol. 134, pp. 111128-111128
Open Access | Times Cited: 106
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Daniela Tomaselli, Alessia Lucidi, Dante Rotili, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 190-244
Open Access | Times Cited: 96
Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Samuele Maramai, Mohamed Benchekroun, Moustafa T. Gabr, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-27
Open Access | Times Cited: 89
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer’s disease
Elisa Zuccarello, Erica Acquarone, Elisa Calcagno, et al.
Biochemical Pharmacology (2020) Vol. 176, pp. 113818-113818
Open Access | Times Cited: 78
Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders
Arun Samidurai, Lei Xi, Anindita Das, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 585-615
Open Access | Times Cited: 55
Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Dongfang Jiang, Tingting Li, Caixia Guo, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
Ahmed K. ElHady, Dalia S. El‐Gamil, Mohammad Abdel‐Halim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1266-1266
Open Access | Times Cited: 24
Role of histone deacetylases and their inhibitors in neurological diseases
Liying Zhang, Sen-Yu Zhang, Ri Wen, et al.
Pharmacological Research (2024), pp. 107410-107410
Open Access | Times Cited: 12
Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents
Márcia S. Pereira, Maria Teresa Cruz, Ana Fortuna, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104052-104052
Open Access | Times Cited: 8
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 19, pp. 8967-9004
Closed Access | Times Cited: 78
HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination
Martin G. Strebl, Arthur J. Campbell, Wen‐Ning Zhao, et al.
ACS Central Science (2017) Vol. 3, Iss. 9, pp. 1006-1014
Open Access | Times Cited: 69
Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance
Lisha Wang, Bharti Bharti, Rajnish Kumar, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112915-112915
Open Access | Times Cited: 66
An up-to-date overview of computational polypharmacology in modern drug discovery
Rajan Chaudhari, Lon Wolf R. Fong, Zhi Tan, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 9, pp. 1025-1044
Open Access | Times Cited: 65
Epigenetic Modifications in Alzheimer’s Neuropathology and Therapeutics
Michelle Esposito, Goldie Libby Sherr
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 64
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
European Journal of Medicinal Chemistry (2018) Vol. 150, pp. 506-524
Closed Access | Times Cited: 62
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions
Rachel Keszycki, Daniel Fisher, Hongxin Dong
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 59
Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
Angela De Simone, Andrea Milelli
ChemMedChem (2019) Vol. 14, Iss. 11, pp. 1067-1073
Closed Access | Times Cited: 57
Page 1 - Next Page

Scroll to top